ReviewJournal of clinical pathology2002
Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer.
Review in Journal of clinical pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 98 citations in OpenAlex.
- Molecular characterization of chronic inflammatory diseases of the urinary bladder based on next-generation RNA sequencing and digital image analysis.Scientific reports · 2025Article
- A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.European urology open science · 2024Article
- Th1/17 polarization and potential treatment by an anti-interferon-γ DNA aptamer in Hunner-type interstitial cystitis.iScience · 2023Article
- Urine biomarkers in bladder cancer - current status and future perspectives.Nature reviews. Urology · 2023Review
- Deep Learning Models for Cystoscopic Recognition of Hunner Lesion in Interstitial Cystitis.European urology open science · 2023Article
- Review
- Effect of a Low Dose of Carvedilol on Cyclophosphamide-Induced Urinary Toxicity in Rats-A Comparison with Mesna.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.Frontiers in surgery · 2021Review
- The optimal management of variant histology in muscle invasive bladder cancer.Translational andrology and urology · 2020Review
- pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging.Virchows Archiv : an international journal of pathology · 2020Review
- Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR).Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against select bladder cancer cell lines.European journal of medicinal chemistry · 2020Article
- Characteristics and clinical significance of histological variants of bladder cancer.Nature reviews. Urology · 2017Review
- Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer.World journal of urology · 2017Article
- Guizhi Fuling Wan as a Novel Agent for Intravesical Treatment for Bladder Cancer in a Mouse Model.Molecular medicine (Cambridge, Mass.) · 2016Article
- Diagnostically challenging cases: what are atypia and dysplasia?The Urologic clinics of North America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A handful of traditional and newer therapeutic procedures, such as chemotherapy, immunotherapy, radiotherapy, photodynamic and laser treatment, and gene therapy, are used to treat epithelial malignancies of bladder origin. These treatment modalities, used either intravesically or systemically, produce morphological changes in the urothelial mucosa that can be mistaken for carcinoma. The pathologist must be able to separate toxic and drug related alterations from tumour related changes. The clinical history is usually invaluable in this assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.